Established in late 2004 in Toronto, Ontario, Sopherion Canada, Inc. commercializes oncology and oncology-related products acquired and developed by Sopherion Therapeutics. Sopherion Canada is committed to positively affecting the quality of life and health of Canadians.
Myocet received Canadian regulatory approval December 21, 2001 and is indicated for the first-line treatment of metastatic breast cancer in combination with cyclophosphamide.
All product information provided is intended for Canadian healthcare professionals only. If you are not a healthcare professional and would like more information about any of these products, please contact your doctor. Myocet may not be available in countries outside Canada or Europe.
Terms and Conditions